Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone

@article{Wang2014IdentificationON,
  title={Identification of novel multitargeted PPAR$\alpha$/$\gamma$/$\delta$ pan agonists by core hopping of rosiglitazone},
  author={Xue-Jiao Wang and J. Zhang and Shu-Qing Wang and Wei-Ren Xu and Xian-Chao Cheng and Run-Ling Wang},
  journal={Drug Design, Development and Therapy},
  year={2014},
  volume={8},
  pages={2255 - 2262}
}
The thiazolidinedione class peroxisome proliferator-activated receptor gamma (PPARγ) agonists are restricted in clinical use as antidiabetic agents because of side effects such as edema, weight gain, and heart failure. The single and selective agonism of PPARγ is the main cause of these side effects. Multitargeted PPARα/γ/δ pan agonist development is the hot topic in the antidiabetic drug research field. In order to identify PPARα/γ/δ pan agonists, a compound database was established by core… Expand
Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar
The thiazolidinedione class PPARγ agonists as antidiabetic agents are restricted in clinical use because of the side effects such as edema, weight gain, and heart failure. The single and selectiveExpand
In-silico identification of peroxisome proliferator-activated receptor (PPAR)α/γ agonists from Ligand Expo Components database
TLDR
The binding modes of saroglitazar-PPARα/γ complexes are explained and provided structure reference for the research and development of novel PPAR α/γ dual agonists by using molecular docking, ADMET prediction, and molecular dynamics simulation methods. Expand
Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations
TLDR
The results provided an approach to rapidly produce novel PPARα/γ dual agonists which might be a potential lead compound to develop against insulin resistance and hyperlipidemia. Expand
Identification of novel PPARα/γ dual agonists by pharmacophore screening, docking analysis, ADMET prediction and molecular dynamics simulations
TLDR
The results indicated that the CHEMBL230490 might be a potential antidiabetic lead compound and provided a valuable approach in developing novel PPARα/γ dual agonists for the treatment of type 2 diabetes mellitus (T2DM). Expand
To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations
TLDR
Detailed dynamics analyses support that the conformation and dynamics of helix 12 play a critical role in determining the activities of the different types of ligands and may aid in further development of this new generation of medication. Expand
Critical Insight into the Design of PPAR-γ Agonists by Virtual Screening Techniques.
TLDR
It is concluded that to achieve a convincing and reliable design of PPAR-γ agonist by virtual screening techniques, customized workflow comprising of appropriate models is essential in which methods may be applied either sequentially or simultaneously. Expand
Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.
  • Merilin Al Sharif, P. Alov, +6 authors I. Pajeva
  • Chemistry, Medicine
  • Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • 2018
TLDR
In silico studies, strongly suggest possible involvement of PPARγ-mediated mechanisms in the in vivo antidiabetic and antioxidant effects of PSM from A. corniculatus Bieb. Expand
Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets
TLDR
This minireview aims to provide fresh perspectives for the development of a new generation of safe insulin sensitizers and describes the potential targets of these agents. Expand
Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among Moringa oleifera Phytochemicals by Virtual Screening, Molecular Docking Analysis, ADME/T-Based Prediction, and In Vitro Analyses
TLDR
This study provides a reference for exploring the molecular mechanisms underlying the anti-diabetic activity of MO, and obtained DPP-IV inhibitors could be used for structural optimization and in-depth in vivo evaluation. Expand
Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.
TLDR
Methods relevant for predictive toxicology and computer-aided drug design and applied to study interactions between peroxisome proliferator-activated receptor γ (PPARγ) and its ligands allowing both to predict potential PPARγ-mediated hepatotoxicity of receptor's full agonists, thus supporting hazard characterization. Expand
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
TLDR
An integrated in silico/in vitro workflow based on pharmacophore- and structure-based virtual screening of the ZINC library, coupled with competitive binding and transactivation assays, and adipocyte differentiation and gene expression studies revealed a gene regulatory profile that was to a large extent unique, however functionally closer to that of a partial agonist. Expand
Structure-based identification of novel PPAR gamma ligands.
TLDR
A structure-based approach was used to screen the subset 'Drugs-Now' of ZINC database and showed that the residues H323, H449, Y327, Y473, K367 and S289 are key structural elements for the molecular recognition of these ligands and the polar arm of PPARγ binding pocket. Expand
Mode of Peroxisome Proliferator-Activated Receptor γ Activation by Luteolin
TLDR
It is proposed that activities of luteolin are related to its singular binding mode, that anti-inflammatory activity does not require H12 stabilization, and that the structure can be useful in developing safe selective PPARγ modulators. Expand
Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach
TLDR
By means of the powerful “core hopping” and “glide docking” techniques, a novel class of PPAR dual agonists was discovered based on the compound GW409544, a well-known dual agonist for both PPAR-alpha andPPAR-gamma modified from the farglitazar structure, which had more favorable conformation for binding to the two receptors. Expand
Safety issues and prospects for future generations of PPAR modulators.
TLDR
This review mainly focuses on the preclinical and clinical adverse events of PPAR agonists that could be of concern when considering the development of new PPar agonists. Expand
Docking, synthesis and anti-diabetic activity of novel sulfonylhydrazone derivatives designed as PPAR-gamma agonists.
TLDR
The virtual screening and synthesis of a novel series of sulfonylhydrazone derivatives designed as peroxisome proliferator-activated receptor gamma (PPARγ) agonists and investigation of the analogs for hypoglycemic activity in a murine model of diabetes reveal a PPARγ ligand that is effective for treatment of diabetic neuropathy in STZ-injected rats. Expand
Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics
TLDR
Ten novel compounds found by targeting peroxisome proliferator-activated receptors (PPARs) using virtual screening and core hopping approaches are reported, finding that these novel dual agonists not only possessed the same function as ragaglitazar did in activating PPARα and PPARγ, but they also had more favorable conformation for binding to the two receptors. Expand
Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
TLDR
A virtual screening workflow based on a combination of pharmacophore modeling with 3D shape and electrostatic similarity screening techniques is able to enrich novel scaffolds for PPAR ligands that could be useful for drug development in the area of atherosclerosis, dyslipidaemia, and type 2 diabetes. Expand
Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding
TLDR
This analysis suggests general strategies for selective PPARδ ligand design and suggests that bulky substituents that line the PPARα and γ ligand binding pockets as structural barriers for GW0742 binding are suggested. Expand
Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses
TLDR
The hypothesis that in a wide range of brain disorders, PPARβ/δ plays a central role between PPARα and PPARγ is proposed, which is designated the "PPAR triad". Expand
...
1
2
3
4
5
...